Innovating Works

Hibernating_Synapses

Financiado
Synaptic resilience in Tau-induced neurodegeneration
Dementia is an enormous burden on society. Patients require life-long care and there is no cure or symptomatic treatment. At early phases, dementia is closely associated with synaptic degeneration and this correlates well with Tau... Dementia is an enormous burden on society. Patients require life-long care and there is no cure or symptomatic treatment. At early phases, dementia is closely associated with synaptic degeneration and this correlates well with Tau pathology in >20 Tauopathies. Interestingly, historic observations in hamsters and squirrels show that when they enter into hibernation, they also display Tau pathology and synaptic loss. Pathologists have pointed to these similarities; however, there is an important difference: synaptic loss is progressive in dementia, but reversible in hibernating animals. Capitalizing on recent technological advancements, I will unravel the mechanisms of this remarkable, yet understudied process of synaptic remodeling in hibernation and then use the pathways that reverse synapse loss in hamsters, to counteract Tau-induced synaptic decline in models of dementia. We will achieve these goals by first defining and studying the molecular and cellular drivers of synaptic remodeling during cycles of hibernation. This is based on innovative spatial transcriptomic and synaptic proteome analyses in hamster brains. We will then identify the human homologues of the hamster genes that reverse synaptic loss following hibernation and use a selection strategy in xenotransplanted human neurons and functional assays on custom-designed multielectrode arrays, to isolate genes rescuing Tau-induced neurodegeneration. This approach is bold, but feasible; my lab has a record of accomplishment in synaptic and neurodegeneration research and we already have strong preliminary work implicating specific pre-synaptic pathways in the types of Tau-dependent synaptic remodeling that we will study here. The gain is that we will uncover the mechanisms of a remarkable process of synaptic resilience, and apply this to rescue the synaptic loss in neurodegeneration. This project will define a conceptually new and unexplored class of therapeutic targets to tackle Tau-induced neuronal decline. ver más
31/12/2027
3M€
Duración del proyecto: 66 meses Fecha Inicio: 2022-06-16
Fecha Fin: 2027-12-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-16
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2021-ADG: ERC ADVANCED GRANTS
Cerrada hace 3 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5